BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda
- Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.
- BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.
- BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.
- BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.
- Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –
